Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075195 | 0.86 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26412236 | 0.79 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16055405 | 0.78 | CA12 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL190911 | 0.77 | CA12 (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6883641 | 0.77 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9328767 | 0.77 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27433650 | 0.76 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30385269 | 0.76 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30299161 | 0.76 | BCL2L1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2805615 | 0.76 | BCL2L1 (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BCL2L1, BAK1 | CA12 4844/4885CA1 4642/4885CA2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.